{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:52:32Z","timestamp":1791881552366,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaad.2025.11.064","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:40:59Z","timestamp":1764175259000},"page":"1126-1133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2"],"prefix":"10.1016","volume":"94","author":[{"given":"Maryanne","family":"Senna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chiasserini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Kolodsick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.11.064_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.jaad.2025.11.064_bib2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","article-title":"Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis","volume":"88","author":"Okhovat","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.064_bib3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","article-title":"Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review","volume":"11","author":"Mostaghimi","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.064_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.064_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","article-title":"\u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata","volume":"4","author":"Aldhouse","year":"2020","journal-title":"J Patient Rep Outcomes"},{"issue":"18","key":"10.1016\/j.jaad.2025.11.064_bib6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.064_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.11.064_bib8","doi-asserted-by":"crossref","unstructured":"Kwon O, Senna MM, Sinclair R, et al. Long-term efficacy of baricitinib in patients with severe alopecia areata: week 52 results from BRAVE-AA1 and BRAVE-AA2. Paper presented at: American Academy of Dermatology Annual Meeting; March 25-29, 2022; Boston, MA.","DOI":"10.1016\/j.jaad.2022.06.243"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.064_bib9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.064_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.064_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.11.064_bib12","series-title":"Paper presented at: American Academy of Dermatology 81st Annual Meeting","article-title":"Safety analysis of baricitinib in adult patients with severe alopecia areata from 2 randomized clinical trials over a median of 1.6 years and up to 3.6 years of exposure","author":"King","year":"2023"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.064_bib13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2","volume":"38","author":"Senna","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2025.11.064_bib14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","article-title":"Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata","volume":"21","author":"Wyrwich","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.11.064_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/bjd.19024","article-title":"Development of the Scalp Hair Assessment PRO\u2122 measure for alopecia areata","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.11.064_bib16","series-title":"Paper presented at: Fall Clinical Dermatology Conference","article-title":"Outcomes of down-titration in patients with severe scalp alopecia areata treated with baricitinib: an update through week 152 from BRAVE-AA2","author":"King","year":"2023"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.064_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaad.2021.12.009","article-title":"Placebo group regrowth rate in alopecia areata clinical trials: a systematic review and meta-analysis","volume":"87","author":"Han","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.11.064_bib18","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/jvc2.455","article-title":"Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials","volume":"3","author":"Zlotogorski","year":"2024","journal-title":"JEADV Clinical Practice"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.064_bib19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaad.2021.02.071","article-title":"Alopecia areata flare patterns in children and young adults while on systemic tofacitinib","volume":"86","author":"McKenzie","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.11.064_bib20","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1111\/jocd.14581","article-title":"Recurrence of alopecia areata after COVID-19 vaccination: a report of three cases in Italy","volume":"20","author":"Rossi","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.11.064_bib21","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamadermatol.2024.2734","article-title":"Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial","volume":"160","author":"King","year":"2024","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:27:15Z","timestamp":1791880035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225032773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0190962225032773"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.064","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}